H. Lundbeck A/S - نتائج البحث

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

bleomycin lundbeck

lundbeck limited - withdrawn form - 5 milligram

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

bleomycin lundbeck injection

lundbeck limited - bleomycin sulfate - pdr for soln inj/inf - 15 milligram

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

ccnu lundbeck capsules

lundbeck limited - lomustine - capsule - 10 milligram

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

xenazine- tetrabenazine tablet

lundbeck pharmaceuticals llc - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - xenazine is indicated for the treatment of chorea associated with huntington’s disease. xenazine is contraindicated in patients: - who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. - taking monoamine oxidase inhibitors (maois). xenazine should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. - taking reserpine. at least 20 days should elapse after stopping reserpine before starting xenazine [see drug interactions (7.2)]. - taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. risk summary there are no adequate data on the developmental risk associated with the use of xenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspri